BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanthala S, Banappagari S, Gokhale A, Liu YY, Xin G, Zhao Y, Jois S. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer. Chem Biol Drug Des 2015;85:702-14. [PMID: 25346057 DOI: 10.1111/cbdd.12453] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Naik H, Sonju JJ, Singh S, Chatzistamou I, Shrestha L, Gauthier T, Jois S. Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy. Pharmaceuticals (Basel) 2021;14:221. [PMID: 33800723 DOI: 10.3390/ph14030221] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Singh SS, Mattheolabakis G, Gu X, Withers S, Dahal A, Jois S. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models. Eur J Med Chem 2021;216:113312. [PMID: 33667849 DOI: 10.1016/j.ejmech.2021.113312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dhritlahre RK, Saneja A. Recent advances in HER2-targeted delivery for cancer therapy. Drug Discov Today 2021;26:1319-29. [PMID: 33359114 DOI: 10.1016/j.drudis.2020.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Shrestha L, Singh SS, Parajuli P, Dahal A, Mattheolabakis G, Meyer S, Bhattacharjee J, Jois SD. In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC. J Cancer 2020;11:5982-99. [PMID: 32922539 DOI: 10.7150/jca.46320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Sable R, Jambunathan N, Singh S, Pallerla S, Kousoulas KG, Jois S. Proximity ligation assay to study protein-protein interactions of proteins on two different cells. Biotechniques 2018;65:149-57. [PMID: 30227746 DOI: 10.2144/btn-2018-0049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
6 Dong Y, Li W, Gu Z, Xing R, Ma Y, Zhang Q, Liu Z. Inhibition of HER2-Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2-Glycan-Imprinted Nanoparticles. Angew Chem Int Ed Engl 2019;58:10621-5. [PMID: 31166063 DOI: 10.1002/anie.201904860] [Cited by in Crossref: 51] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
7 Dong Y, Li W, Gu Z, Xing R, Ma Y, Zhang Q, Liu Z. Inhibition of HER2‐Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2‐Glycan‐Imprinted Nanoparticles. Angew Chem 2019;131:10731-5. [DOI: 10.1002/ange.201904860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
8 Miki Y, Iwabuchi E, Ono K, Sasano H, Ito K. Exploring Protein⁻Protein Interaction in the Study of Hormone-Dependent Cancers. Int J Mol Sci 2018;19:E3173. [PMID: 30326622 DOI: 10.3390/ijms19103173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
9 Naik H, Gauthier T, Singh S, Jois S. Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer. Bioorg Med Chem Lett 2018;28:3506-13. [PMID: 30314880 DOI: 10.1016/j.bmcl.2018.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kanthala SP, Liu YY, Singh S, Sable R, Pallerla S, Jois SD. A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization. Oncotarget 2017;8:74244-62. [PMID: 29088782 DOI: 10.18632/oncotarget.19013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
11 Zeng L, Pan Y, Zou R, Zhang J, Tian Y, Teng Z, Wang S, Ren W, Xiao X, Zhang J, Zhang L, Li A, Lu G, Wu A. 808 nm-excited upconversion nanoprobes with low heating effect for targeted magnetic resonance imaging and high-efficacy photodynamic therapy in HER2-overexpressed breast cancer. Biomaterials 2016;103:116-27. [DOI: 10.1016/j.biomaterials.2016.06.037] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 10.7] [Reference Citation Analysis]
12 Gaborit N, Lindzen M, Yarden Y. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother 2016;12:576-92. [PMID: 26529100 DOI: 10.1080/21645515.2015.1102809] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
13 Kanthala S, Mill CP, Riese DJ 2nd, Jaiswal M, Jois S. Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. Protein Expr Purif 2016;125:26-33. [PMID: 26363121 DOI: 10.1016/j.pep.2015.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Timmermans-Sprang EP, Gracanin A, Mol JA. High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression. BMC Cancer 2015;15:545. [PMID: 26205886 DOI: 10.1186/s12885-015-1544-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
15 Sable R, Jois S. Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors. Molecules 2015;20:11569-603. [PMID: 26111183 DOI: 10.3390/molecules200611569] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]